Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 16;12(1):15566.
doi: 10.1038/s41598-022-18805-5.

Predicting conversion to Alzheimer's disease in individuals with Mild Cognitive Impairment using clinically transferable features

Affiliations

Predicting conversion to Alzheimer's disease in individuals with Mild Cognitive Impairment using clinically transferable features

Ingrid Rye et al. Sci Rep. .

Abstract

Patients with Mild Cognitive Impairment (MCI) have an increased risk of Alzheimer's disease (AD). Early identification of underlying neurodegenerative processes is essential to provide treatment before the disease is well established in the brain. Here we used longitudinal data from the ADNI database to investigate prediction of a trajectory towards AD in a group of patients defined as MCI at a baseline examination. One group remained stable over time (sMCI, n = 357) and one converted to AD (cAD, n = 321). By running two independent classification methods within a machine learning framework, with cognitive function, hippocampal volume and genetic APOE status as features, we obtained a cross-validation classification accuracy of about 70%. This level of accuracy was confirmed across different classification methods and validation procedures. Moreover, the sets of misclassified subjects had a large overlap between the two models. Impaired memory function was consistently found to be one of the core symptoms of MCI patients on a trajectory towards AD. The prediction above chance level shown in the present study should inspire further work to develop tools that can aid clinicians in making prognostic decisions.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
2 × 2 confusion matrices computed for the sMCI and cAD labels returned from prediction on test set compared with the co-occurrences of the observed outcome. The black and purple cells represent misclassified subjects, while the beige and red cells represent correctly classified subjects. The number of occurrences in each cell is given as number of subjects and percentage of the total test set for RF model and ensemble.
Figure 2
Figure 2
The figure illustrates the two models’ overlap in misclassified sMCI (a) og cAD (b). Gray symbols represent subjects for which the two models overlapped in misclassification. Purple and blue symbols represents additional subjects misclassified by the Random Forest model and the ensemble model, respectively.
Figure 3
Figure 3
Feature importances calculated by decrease in impurity from evaluation on test set. All the predictors included in the model are displayed on the y-axis while the x-axis depicts their relative importance.

References

    1. Huang L-K, Chao S-P, Hu C-J. Clinical trials of new drugs for Alzheimer disease. J. Biomed. Sci. 2020;27:1–13. doi: 10.1186/s12929-019-0609-7. - DOI - PMC - PubMed
    1. 2022 Alzheimer’s disease facts and figures. Alzheimer’s Dement.18, 700–789, (2022). 10.1002/alz.12638 - PubMed
    1. Sperling RA, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the national institute on aging-alzheimer’s association workgroups on diagnostic guidelines for alzheimer’s disease. Alzheimer’s Dement. 2011;7:280–292. doi: 10.1016/j.jalz.2011.03.003. - DOI - PMC - PubMed
    1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–259. doi: 10.1007/BF00308809. - DOI - PubMed
    1. Amini Y, Saif N, Greer C, Hristov H, Isaacson R. The role of nutrition in individualized Alzheimer’s risk reduction. Curr. Nutr. Rep. 2020;9:55–63. doi: 10.1007/s13668-020-00311-7. - DOI - PubMed

Publication types

Substances